PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$35.40 USD
-0.41 (-1.14%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $35.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 41 - 60 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Full SMA Data Presented at WMS; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Staying on the Sidelines Ahead of the ACT-DMD Readout
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Lumpy Patient Build, a Lot Riding on Phase 3 Read (4Q15)
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna Launch on Track in Europe with Pivotal Trial Data Ahead in 4Q15; Reiterate OUTPERFORM and $81 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Opportunity for Investors with High Risk Tolerance
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Looking Backwards and Forwards in the Treatment of DMD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
ISIS Sets the Bar High in SMA, Reiterate Neutral
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
German Assessment of Translarna Supportive of EMA Decision
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna Reimbursement In Germany to Continue Until June 1st 2016
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.